Price
No data yet.
Social Signal Score
Analyst Ratings
13 analystsRevenue
$240.34M+630766.76%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Michael S. Weiss
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 399
- Beta
- 1.66
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 5.31
Financials
Revenue
$240.34M+630766.8%Net Income
$7.78MEBITDA
$21.67MFree Cash Flow
$21.02MEPS (diluted)
$0.05Shares Outstanding (diluted)
157.28M+219.7%Operating Expenses
$177.47MCash & Debt
$552.25MReturn of Capital
$99.99MRevenue by Segment (annual)
$616.29MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $616.29M | $447.18M | $3.10 |
| 2024 | $329.00M | $23.38M | $0.16 |
| 2023 | $233.66M | $12.67M | $0.09 |
| 2022 | $2.79M | $-223.81M | $-1.46 |
| 2021 | $6.69M | $-348.10M | $-2.63 |
| 2020 | $152.0K | $-279.38M | $-2.42 |
| 2019 | $152.0K | $-172.87M | $-1.96 |
| 2018 | $152.0K | $-173.48M | $-2.30 |
| 2017 | $152.4K | $-118.48M | $-1.91 |
| 2016 | $152.4K | $-78.25M | $-1.60 |
| 2015 | $152.4K | $-62.95M | $-1.38 |
| 2014 | $152.4K | $-55.78M | $-1.64 |
| 2013 | $152.4K | $-20.48M | $-0.81 |
| 2012 | $19.0K | $-18.07M | $-1.38 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $4.55
- Implied price
- $45.53
- Return from $54.29
- -3.5% a year
To earn 15.0% a year on these assumptions you'd need to buy at $22.64 — -58.3% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 6 | 8 | 10 | 12 | 14 |
|---|---|---|---|---|---|
| -2.0% | -20.9% | -16.2% | -12.4% | -9.1% | -6.3% |
| 3.0% | -16.9% | -11.9% | -7.9% | -4.5% | -1.5% |
| 8.0% | -12.8% | -7.7% | -3.5% | 0.1% | 3.3% |
| 13.0% | -8.8% | -3.4% | 1.0% | 4.8% | 8.0% |
| 18.0% | -4.8% | 0.9% | 5.5% | 9.4% | 12.8% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
55+10.00%Social Signal Score
Mentions (8)
- Newsmarketbeat.com·18d ago·Neutral
TG Therapeutics Eyes $1B Run Rate as BRIUMVI Gains MS Market Share TG Therapeutics NASDAQ: TGTX Chairman, President and Chief Executive Officer Mike Weiss said the company's multiple sclerosis therapy, BRIUMVI, has captured more than one-third of the intravenous anti-CD20 market and continues to gain share as it approaches its fourth full year on the market.
View source ↗ - News (RSS)yahoo·34d ago·Positive
IBD Stock Of The Day, TG Therapeutics, Eyes Breakout After Topping Early Buy Point
View source ↗ - Newszacks.com·34d ago·Neutral
TG Therapeutics (TGTX) Up 15.1% Since Last Earnings Report: Can It Continue? TG Therapeutics (TGTX) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newsseekingalpha.com·41d ago·Positive
TG Therapeutics: Briumvi's Peak May Be Far Away (Rating Upgrade) TG Therapeutics, Inc.'s Q4 2026/H1 2027 will be rich in catalysts. From the presentation of preliminary Phase 1 azer-cel data in progressive MS in the second half of 2026 to topline Phase 3 data for Briumvi SC by year-end 2026/early 2027. TG Therapeutics raised its Briumvi U.S. net product revenue from $885-$900 million to $890-$905 million.
View source ↗ - News (RSS)yahoo·43d ago·Positive
TGTX Stock Outperforms 95% of Stocks. Here's Why.
View source ↗ - News (RSS)seekingalpha·45d ago·Positive
TG Therapeutics: Briumvi's Growth Attracts Buyout Rumors
View source ↗ - Newsseekingalpha.com·45d ago·Positive
TG Therapeutics: Briumvi's Growth Attracts Buyout Rumors Shares of TG Therapeutics rose this week after buyout rumors surfaced. TG is a prime takeover target, fueled by Briumvi's growth and recent subcutaneous formulation de-risking. I see a potential acquisition premium of at least 45-50%, valuing TGTX at $73-76 per share, with strong standalone prospects regardless of M&A outcomes.
View source ↗ - News (RSS)yahoo·45d ago·Neutral
TGTX Stock Alert: What to Know as Takeover Rumors Swirl Around TG Therapeutics
View source ↗
Earnings
Mon, Nov 2(in 4 weeks)
Consensus estimate $0.36 per share
Typical surprise -46.9% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 3$0.05 vs $0.31miss
- Wed, May 6$0.14 vs $0.23miss
- Thu, Feb 26$0.14 vs $0.35miss
- Mon, Nov 3$2.43 vs $0.24beat
- Mon, Aug 4$0.17 vs $0.32miss
- Mon, May 5$0.03 vs $0.18miss
Estimates and results for TGTX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TGTX officers and directors.
- Bought
- $1.1m
- Sold
- $16.8m
2 trades
24 trades
- Charney Laurence Nsold
- Echelard Yannsold
- Lonial Sagarsold
- Echelard Yannsold
- Power Sean Asold
- Power Sean Asold
- Lonial Sagarsold
- Charney Laurence Nsold
74 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Chris Jacobshouse · NY27 · disclosed Nov 6, 2020 (59d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.